REGN | Stock Discussion Forums

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical
REGN

An SI Board Since March 1997

Posts	SubjectMarks	Bans	Symbol
18	1	0	REGN

Emcee: K.J.Devine	Type: Unmoderated

Introduction Market Data Compact

Started By: K.J.Devine
Date: Mar 9 1997 2:58PM EST

Amgen-Regeneron. Takeover possible by second quarter 1997. Amgen will take over "REGN", team up to to test DNF based products.

Amgen-Regeneron Partners as a treatment for ALS, delivered Intrathecally (directly into the spinal fluid), a route of delivery that may yield better results than subcutaneous delivery. Amgen is also testing BDNF in early stage, small European trials on Guillain
Barre syndrome and diabetic neuropathy. Both these conditions involve peripheral neurons, which may allow for successful treatment via subcutaneous delivery. Amgen is conducting an early-stage NT-3 trial in diabetic neuropathy on behalf of Amgen-Regeneron Partners and plans to start a trial in chemotherapy-induced neuropathy during the first half of 1997. The company anticipates announcing preliminary
results of the NT-3 diabetic neuropathy study later in 1997.

Amgen said that ongoing preclinical studies with glial derived neurotrophic factor(GDNF)in Parkinson's disease are continuing to yield encouraging results that support the rationale for ongoing clinical development of the drug in this disease and Phase 1
safety data is expected by year end. Amgen previewed early preclinical research in protection against hearing loss, a significant disability for 25 million people in the United States.

Procter & Gamble invested $10 million in the company and will support $3.75 million of annual research at Regeneron for up to five years.

In addition, annual payments are expected from Procter & Gamble for research support and from Merck & Co. Inc. for contract manufacturing of an intermediate for an approved Merck pediatric vaccine. "

Regeneron's total revenue in the fourth quarter of 1996 increased to $6.5 million from $5.7. million in the same period of 1995. The increase was due to higher investment income and an increase in contract manufacturing revenue from a long-term manufacturing agreement with Merck & Co. Inc.

K.J.Devine

Go to reply# or date (mm/dd/yy):

Reply	Message Preview	From	Recs	Posted
18	shdu, From when is s-TNF-alfa-r antibody (IMNX) protease inhibitor?????? You s	Miljenko Zuanic	-	6/10/1997
17	John, Sorry, I don't know Paracelsian very well. I read through their home	shdu	-	6/10/1997
16	Sam: Please forgive my intrusion but have been trying to find latest info re tr	JOHN F. MORGAN	-	5/15/1997
15	Try the other thread, the REGENERON thread.......	scaram(o)uche	-	5/14/1997
14	GOOD NEWS!! I CANT WAIT TIL THE OPENING ON WEDNESDAY!!! IT MAY OPEN AT 14 +++++	sean	-	5/13/1997
13	Im surprised no one posted this news today: P&G And Regeneron Form 10-Year	Tracker	-	5/13/1997
12	Got this from a friend (thanks, Mike). Being downstream in the signaling pathw	scaram(o)uche	-	4/8/1997
11	Rick, Agreed. REGN has over 300 employees with production plant worth over 20M	Miljenko Zuanic	-	4/6/1997
10	Richard, I agree with you that most projects in biotechs have rational scienti	shdu	-	4/6/1997
9	Sam: Your comments would imply that most projects at companies like Sugen, Ari	scaram(o)uche	-	4/5/1997
8	Yes Richard, they have to be intracellular or at least membrane associated. Oth	shdu	-	4/5/1997
7	Sam..... Do you think that molecules need be extracellular or membrane-associa	scaram(o)uche	-	4/5/1997
6	April 5 announcement of MAP kinase is a non-event. There are so many kinases. J	shdu	-	4/5/1997
5	Well, not to take away anything that K. J. Devine started... And I'm prett	Patrick Slevin	-	4/5/1997
4	Yes, they are very good at marketing, but they have nothing in the inventory th	shdu	-	4/5/1997
3	From a marketing point of view I think the company is well-connected and has gr	Patrick Slevin	-	4/4/1997
2	Regeneron is a one man show, namely George Yancapolos, the chief scientist. He	shdu	-	4/4/1997
1	Okay, I'll take the bait. Why do you think Amgen will take over REGN? I kn	Patrick Slevin	-	3/24/1997

Go to reply# or date (mm/dd/yy):